Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Editor’s note: Dr. Hudis hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity.
Dr. Elizabeth M. Blanchard outlines hot-button health policy issues that are likely to be legislative priorities in U.S. states during 2019-2020. Your voice can make an impact on these issues at the state level.
Social injustice is perpetuated when patients can't afford to participate in essential clinical research.
At a recent meeting, the ASCO delegation to the AMA House of Delegates presented concerns focused on the Competitive Acquisition Program (CAP), among a variety of other issues.
Each year, we call upon the ASCO members to place your votes to select our Society’s future leaders. This year, we are asking that you not only vote for the open leadership positions, but also for a proposed bylaw change.
The chair-elect of the ASCO Health Equity Committee and I discuss concerns with proposed Medicaid work requirements and their impact on patients with cancer and their physicians.
This program’s application period closes on September 25, so apply today if you are interested in being a leader in shaping cancer policy.
We remain very concerned that the CMS proposal could harm Medicare beneficiaries who have cancer by triggering major cuts to physician reimbursement, especially for Part B drugs and for drugs that have been newly introduced to the market.
ASCO's "I Live to Conquer Cancer" campaign is putting a human face on the results of cancer research and the researchers who make this progress.
I am really pleased to have with us ASCO's Chief Medical Officer and Senior Vice President for a conversation focusing on right-to-try policies.
At the most recent meeting, ASCO's delegation to the AMA House of Delegates were involved in resolutions related to Pharmacy Benefit Managers, opioids, billing for survivorship care plans, alcohol as a modifiable risk for cancer, and more.
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and approval of new therapies should be applauded. 
My presidential year has provided me with the chance to advocate for ASCO’s principles to support our members and our patients. 
We examine how state-level health care policy may impact the care that we deliver to our patients with cancer, and why it's important for us to pay attention to and help shape bills and regulations moving in states.
Our vice president of Clinical Affairs breaks down the reporting changes you need to understand and address to avoid potential financial penalties in 2020.
All of us have the power to impact health care policy. ASCO's Advocate of the Year explains how easy it is to get involved, and how we need to focus on long-term success.

Pages


Advertisement